GO:0032732 positive regulation of interleukin-1 production: Inflammatory Cytokine Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032732 describes any process that activates or increases the frequency, rate, or extent of interleukin-1 production, including IL-1 biosynthesis and secretion.
• Interleukin-1 (IL-1) is a master proinflammatory cytokine produced primarily by blood monocytes and tissue macrophages.
• Positive regulation of IL-1 production is driven by pattern recognition receptors, inflammasome activation, and cytokine feedback loops that converge on NF-kB and MAPK signaling.
• Dysregulated IL-1 production contributes to autoimmune diseases such as systemic lupus erythematosus, psoriasis, osteoarthritis, and multiple myeloma.
• Key genes controlling this process include IL1B, NLRP3, PYCARD, CASP1, IRAK1, MYD88, and HMGB1, which can be targeted by CRISPR knockout or knock-in models.
• Studying GO:0032732 requires integrated methods such as cytokine ELISA, RNA-seq, inflammasome assays, and CRISPR library screening to identify causal regulators.
Description
GO:0032732, positive regulation of interleukin-1 production, is a Gene Ontology biological process term that encompasses any molecular event that activates or increases the frequency, rate, or extent of interleukin-1 (IL-1) production. IL-1 is a pleiotropic cytokine that mediates acute and chronic inflammation, and its production is tightly controlled at transcriptional, post-transcriptional, and secretory levels. Understanding the positive regulation of IL-1 production is critical because excessive IL-1 signaling is a hallmark of numerous inflammatory and autoimmune disorders. IL-1 production is primarily attributed to blood monocytes and tissue macrophages, although keratinocytes, chondrocytes, and renal tubular cells can also contribute under specific conditions. The process includes both the biosynthesis of the IL-1 pro-peptide and its subsequent secretion, often through unconventional pathways such as autophagy-based release of HMGB1 that amplifies IL-1 production in psoriatic skin inflammation. Positive regulation can be triggered by pathogen-associated molecular patterns, damage-associated molecular patterns, and cytokines that activate NF-kB and inflammasome components. For researchers, GO:0032732 provides a structured framework to annotate genes and pathways that amplify IL-1 output. This is essential for dissecting disease mechanisms in autoimmunity, cancer, and metabolic disorders, and for developing targeted therapies that dampen pathological IL-1 production without compromising host defense.
positive regulation of interleukin-1 production At A Glance
| GO ID | GO:0032732 |
|---|---|
| GO term | positive regulation of interleukin-1 production |
| Ontology | biological_process |
| Synonym | activation of interleukin-1 production; positive regulation of IL-1 production; positive regulation of interleukin-1 biosynthetic process; positive regulation of interleukin-1 secretion; stimulation of interleukin-1 production; up regulation of interleukin-1 production; up-regulation of interleukin-1 production; upregulation of interleukin-1 production |
| Major function | Upregulation of IL-1 cytokine biosynthesis and secretion in response to inflammatory stimuli |
| Primary cell types | Blood monocytes, tissue macrophages, keratinocytes, renal tubular cells, chondrocytes |
| Key signaling pathways | NF-kB, MAPK, inflammasome (NLRP3/CASP1), TLR/IRAK1/MyD88 |
| Disease relevance | Psoriasis, systemic lupus erythematosus, osteoarthritis, multiple myeloma, diabetic nephropathy |
What Is GO:0032732?
In our own words, GO:0032732 refers to any biological process that stimulates, enhances, or upregulates the production of interleukin-1 cytokines, including both the biosynthetic process and the secretion of IL-1 family members. This term covers signaling events, transcriptional activation, and post-translational mechanisms that increase the amount of IL-1 available for receptor binding and downstream inflammatory signaling.
Why Is positive regulation of interleukin-1 production Important in Cell Biology?
Positive regulation of interleukin-1 production is a central node in inflammatory biology because IL-1 amplifies immune responses and drives tissue damage when uncontrolled. Many chronic diseases, including autoimmune disorders and cancers, show elevated IL-1 production that correlates with disease severity and poor outcomes. Targeting the positive regulators of IL-1 production offers a therapeutic strategy to interrupt pathological inflammation at its source.
• IL-1 is a master proinflammatory cytokine, and its overproduction is linked to fever, acute-phase response, and tissue destruction.
• Positive regulation of IL-1 production is required for host defense against pathogens but becomes detrimental in chronic inflammatory diseases.
• In systemic lupus erythematosus, upregulated IRAK1 enhances IL-1 signaling and Th17 differentiation, making this pathway a therapeutic target.
• Psoriatic skin inflammation involves autophagy-based HMGB1 secretion by keratinocytes, which positively regulates IL-1 production and sustains the inflammatory loop.
• Osteoarthritis progression is driven by IL-1 beta, and tailored exosome cargo can remodel the proinflammatory microenvironment by regulating IL-1 production.
• In diabetic nephropathy, Trem2+ macrophages repress IL-1 beta-mediated CD36 expression, highlighting the importance of negative regulation of IL-1 production.
• Multiple myeloma pathogenesis is critically dependent on IL-1 beta, which promotes tumor growth and bone destruction.
• IL-1 production by blood monocytes is a key biomarker for inflammatory disease activity and response to therapy.
• Understanding positive regulation of IL-1 production enables the design of CRISPR screens to identify novel regulators.
• Modulating this process with gene editing tools can validate drug targets and advance precision medicine for inflammatory diseases.
What Happens During positive regulation of interleukin-1 production?
Initiation by Pattern Recognition Receptors
In simple terms: The process starts when immune sensors detect danger signals from microbes or damaged cells.
Positive regulation of IL-1 production is initiated when pattern recognition receptors such as Toll-like receptors (TLRs) recognize pathogen-associated molecular patterns or damage-associated molecular patterns. This recognition triggers intracellular signaling cascades that involve the adaptor protein MyD88 and the kinase IRAK1, leading to activation of NF-kB and MAPK pathways. In blood monocytes, this activation is a primary mechanism for inducing IL-1 beta production.
Inflammasome Activation and Caspase-1 Cleavage
In simple terms: A molecular platform called the inflammasome activates an enzyme that cuts pro-IL-1 into its active form.
Following transcriptional upregulation of IL1B, the NLRP3 inflammasome assembles with the adaptor PYCARD (ASC) and pro-caspase-1, leading to caspase-1 activation. Active caspase-1 cleaves pro-IL-1 beta into mature IL-1 beta, which is then secreted. This step is a critical positive regulatory node because it controls the amount of bioactive IL-1 released.
Transcriptional and Post-transcriptional Amplification
In simple terms: Cells increase the production of IL-1 by making more mRNA and stabilizing it.
NF-kB and MAPK signaling promote transcription of the IL1B gene and stabilize its mRNA, increasing the pool of pro-IL-1 beta available for processing. In keratinocytes, autophagy-based unconventional secretion of HMGB1 acts as a positive regulator that amplifies IL-1 production and sustains psoriatic skin inflammation. This amplification loop is a key target for anti-inflammatory therapies.
Secretion and Extracellular Feedback
In simple terms: The mature IL-1 is released from the cell and can stimulate more IL-1 production in neighboring cells.
Mature IL-1 beta is secreted through unconventional pathways, and extracellular IL-1 binds to IL-1 receptor, activating NF-kB and further enhancing IL-1 production in a positive feedback loop. In osteoarthritis, IL-1 beta tailored exosome cargo can remodel the proinflammatory microenvironment, demonstrating how secreted IL-1 perpetuates inflammation. This feedback is a hallmark of chronic inflammatory diseases.
Key Genes Involved in GO:0032732 positive regulation of interleukin-1 production
The following genes and proteins are experimentally validated participants in the positive regulation of interleukin-1 production, based on the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL1B | Encodes pro-IL-1 beta, the primary cytokine whose production is positively regulated | Central target for measuring IL-1 production; knockout and knock-in models validate regulatory mechanisms |
| NLRP3 | Inflammasome sensor that activates caspase-1 for IL-1 beta maturation | Key positive regulator; knockout reduces IL-1 production in inflammatory models |
| PYCARD | Adaptor protein (ASC) linking NLRP3 to caspase-1 | Essential for inflammasome-mediated IL-1 production; knockout abolishes IL-1 release |
| CASP1 | Cysteine protease that cleaves pro-IL-1 beta into active form | Direct positive regulator; knockout prevents mature IL-1 production |
| IRAK1 | Kinase in TLR/IL-1R signaling that activates NF-kB | Upregulated in SLE; inhibition represses Th17 differentiation and IL-1 production |
| MYD88 | Adaptor protein for TLR and IL-1R signaling | Central node for positive regulation; knockout impairs IL-1 production |
| HMGB1 | Nuclear protein secreted by keratinocytes via autophagy, amplifies IL-1 production | Positive regulator in psoriasis; knockout reduces skin inflammation |
| TREM2 | Receptor on macrophages that represses IL-1 beta-mediated CD36 expression | Negative regulator of IL-1 production in diabetic nephropathy |
| CD36 | Scavenger receptor induced by IL-1 beta, involved in lipid accumulation | Downstream effector; its expression is repressed by Trem2+ macrophages |
| IL1R1 | Receptor for IL-1, mediates feedback amplification | Positive feedback loop; knockout blocks IL-1-induced IL-1 production |
| NFKB1 | Transcription factor that drives IL1B transcription | Central transcriptional regulator; knockout reduces IL-1 production |
| MAPK1 | Kinase in MAPK pathway that stabilizes IL-1 mRNA | Positive regulator; inhibition reduces IL-1 production |
| IL1RN | IL-1 receptor antagonist, negative regulator of IL-1 signaling | Knockout leads to excessive IL-1 signaling; relevant for autoinflammatory diseases |
| IL18 | Related IL-1 family cytokine, often co-regulated | Shares inflammasome-dependent processing; knockout models study family-wide regulation |
| GSDMD | Gasdermin D, mediates pyroptotic release of IL-1 | Positive regulator of secretion; knockout reduces extracellular IL-1 |
| TLR4 | Pattern recognition receptor for LPS, triggers IL-1 production | Upstream initiator; knockout abolishes LPS-induced IL-1 |
| IL6 | Cytokine that can amplify IL-1 production in some contexts | Feedback regulator; knockout alters inflammatory milieu |
| TNF | Cytokine that synergizes with IL-1 production | Positive regulator in chronic inflammation; knockout reduces IL-1 levels |
How Is positive regulation of interleukin-1 production Regulated?
Positive regulation of interleukin-1 production is controlled by multiple layers of regulation. At the transcriptional level, NF-kB and MAPK pathways drive IL1B expression in response to TLR/IL-1R signaling through MyD88 and IRAK1. Post-transcriptionally, mRNA stability and microRNAs modulate IL-1 output. At the protein level, inflammasome assembly and caspase-1 activation are tightly regulated by NLRP3, PYCARD, and GSDMD. Negative regulators such as TREM2 in macrophages can repress IL-1 beta-mediated signaling, as shown in diabetic nephropathy. Additionally, autophagy-based secretion of HMGB1 by keratinocytes acts as a positive regulator in psoriatic inflammation. This multilayered regulation ensures that IL-1 production is rapid but transient under normal conditions, and its dysregulation leads to chronic inflammatory diseases.
positive regulation of interleukin-1 production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HMGB1 | Psoriasis; autophagy-based secretion amplifies IL-1 production | Keratinocyte-specific knockout or knock-in of HMGB1 in mouse models |
| IRAK1 | Systemic lupus erythematosus; IRAK1 inhibition represses Th17 differentiation | IRAK1 knockout or point-mutation in T cells and monocytes |
| IL1B | Osteoarthritis; IL-1 beta drives cartilage degradation | IL1B knockout or overexpression in chondrocytes and exosome models |
| TREM2 | Diabetic nephropathy; Trem2+ macrophages repress IL-1 beta-mediated CD36 expression | Trem2 knockout or knock-in in macrophages and renal tubular cells |
| IL1B | Multiple myeloma; IL-1 beta promotes tumor growth and bone destruction | IL1B knockout in myeloma cell lines and bone marrow stromal cells |
Psoriasis and Skin Inflammation
In psoriatic skin inflammation, keratinocytes undergo autophagy-based unconventional secretion of HMGB1, which acts as a pivotal positive regulator of IL-1 production. This amplifies the inflammatory loop and contributes to the characteristic skin lesions. Targeting HMGB1 or its downstream IL-1 production may offer therapeutic benefit.
Systemic Lupus Erythematosus (SLE)
Upregulated IRAK1 in SLE enhances TLR/IL-1R signaling, leading to increased IL-1 production and Th17 differentiation. Inhibition of IRAK1 represses Th17 differentiation, suggesting that positive regulation of IL-1 production is a driver of autoimmunity in SLE.
Osteoarthritis
IL-1 beta is a key mediator of cartilage degradation in osteoarthritis. Remodeling the proinflammatory microenvironment through IL-1 beta tailored exosome cargo can regulate inflammation and promote cartilage regeneration. This highlights the importance of controlling positive regulation of IL-1 production in joint disease.
Multiple Myeloma
IL-1 beta plays a critical role in the pathogenesis of multiple myeloma by promoting tumor cell growth and bone destruction. Positive regulation of IL-1 production in the bone marrow microenvironment contributes to disease progression, making it a therapeutic target.
From positive regulation of interleukin-1 production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene reduce IL-1 production? | CRISPR knockout in monocytes or macrophages followed by LPS stimulation and IL-1 ELISA |
| Does a specific point mutation in NLRP3 alter inflammasome-mediated IL-1 production? | CRISPR point mutation knock-in in iPSC-derived macrophages |
| Does tagging an endogenous IL-1 pathway protein affect its localization and function? | CRISPR knock-in of fluorescent or epitope tags at the endogenous locus |
| Does overexpression of a positive regulator increase IL-1 production? | CRISPR activation or lentiviral overexpression in keratinocytes or chondrocytes |
| Which genes regulate IL-1 production in a genome-wide manner? | CRISPR library screening with IL-1 cytokine readout |
| Can we model disease-specific IL-1 production in human cells? | Patient-derived iPSCs with CRISPR correction of risk variants |
How to Study the positive regulation of interleukin-1 production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | Secreted IL-1 beta and IL-1 alpha protein levels | Quantify IL-1 production after genetic or pharmacological perturbation |
| RNA-seq | IL1B mRNA and global transcriptome changes | Identify transcriptional regulators of IL-1 production |
| Western blot | Pro-IL-1 beta and cleaved IL-1 beta protein | Assess inflammasome-mediated processing |
| Caspase-1 activity assay | Caspase-1 enzymatic activity | Measure inflammasome activation |
| CRISPR knockout screening | Gene essentiality for IL-1 production | Discover novel positive regulators |
| CRISPR activation screening | Gene overexpression effects on IL-1 production | Identify sufficiency of candidate regulators |
| Flow cytometry | Intracellular pro-IL-1 beta and surface markers | Analyze IL-1 production at single-cell level |
| Immunofluorescence | HMGB1 secretion and IL-1 localization | Study unconventional secretion in keratinocytes |
Cytokine Quantification by ELISA
Enzyme-linked immunosorbent assay (ELISA) is the standard method to measure IL-1 beta and IL-1 alpha levels in cell culture supernatants and serum. It is used to assess the impact of genetic perturbations on positive regulation of IL-1 production.
RNA Sequencing and Transcriptomics
RNA-seq measures IL1B mRNA and global transcriptional changes following stimulation. It helps identify pathways that positively regulate IL-1 production and can be combined with CRISPR screens.
Inflammasome Activation Assays
Inflammasome assays detect caspase-1 activation and IL-1 beta cleavage by Western blot or FLICA. These assays are essential to study NLRP3, PYCARD, and CASP1 function in IL-1 production.
CRISPR Library Screening
Genome-wide CRISPR knockout or activation screens coupled with IL-1 cytokine readouts can identify novel positive regulators of IL-1 production. This unbiased approach is powerful for discovering therapeutic targets.
How CRISPR Can Be Used to Study GO:0032732 positive regulation of interleukin-1 production
Knockout
CRISPR knockout of candidate genes such as NLRP3, PYCARD, CASP1, IRAK1, or HMGB1 can determine whether they are required for positive regulation of IL-1 production. For example, IRAK1 knockout in SLE models represses Th17 differentiation and IL-1 production. HMGB1 knockout in keratinocytes reduces psoriatic inflammation.
Point Mutation
CRISPR point mutation knock-in can model disease-associated variants in genes like NLRP3 or IL1B to study their impact on IL-1 production. This approach is useful for validating SNPs identified in autoimmune disease GWAS.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) at the IL1B locus allows real-time tracking of IL-1 production in live cells. Tagged knock-in of inflammasome components can reveal their assembly dynamics.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of positive regulators such as HMGB1 or IRAK1 can test sufficiency for increasing IL-1 production. This is valuable for identifying driver genes in inflammatory diseases.
How EDITGENE Supports positive regulation of interleukin-1 production Research
Researchers studying positive regulation of interleukin-1 production-related genes often need to determine whether a candidate gene is causally involved in IL-1 biosynthesis, processing, or secretion. EDITGENE provides a comprehensive suite of CRISPR gene editing services to enable such functional validation in relevant cell models.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of interleukin-1 production research.
Frequently Asked Questions About positive regulation of interleukin-1 production
What is GO:0032732?
GO:0032732 is the Gene Ontology term for positive regulation of interleukin-1 production, describing any process that activates or increases the frequency, rate, or extent of IL-1 production.
What genes are involved in positive regulation of interleukin-1 production?
Key genes include IL1B, NLRP3, PYCARD, CASP1, IRAK1, MYD88, HMGB1, and TREM2, as shown in studies of inflammation and autoimmunity.
How is interleukin-1 production positively regulated?
It is positively regulated by pattern recognition receptor signaling, inflammasome activation, NF-kB and MAPK pathways, and feedback loops involving secreted IL-1.
What diseases are associated with increased IL-1 production?
Diseases include psoriasis, systemic lupus erythematosus, osteoarthritis, multiple myeloma, and diabetic nephropathy.
What cell types produce interleukin-1?
Blood monocytes and tissue macrophages are primary producers, but keratinocytes, chondrocytes, and renal tubular cells can also produce IL-1 under inflammatory conditions.
How can CRISPR be used to study positive regulation of IL-1 production?
CRISPR knockout, knock-in, point mutation, and overexpression models can test the causal role of candidate genes in IL-1 production.
What methods measure interleukin-1 production?
ELISA, RNA-seq, Western blot, caspase-1 activity assays, and flow cytometry are commonly used to measure IL-1 production.
Is HMGB1 involved in IL-1 production?
Yes, autophagy-based secretion of HMGB1 by keratinocytes positively regulates IL-1 production in psoriatic skin inflammation.
What is the role of IRAK1 in IL-1 production?
IRAK1 is a kinase in TLR/IL-1R signaling that activates NF-kB; its upregulation in SLE enhances IL-1 production and Th17 differentiation.
How does TREM2 affect IL-1 production?
Trem2+ macrophages repress IL-1 beta-mediated CD36 expression in diabetic nephropathy, indicating a negative regulatory role.
Conclusion
GO:0032732 positive regulation of interleukin-1 production is a fundamental biological process that governs the amplification of IL-1 cytokine output in response to inflammatory cues. Its dysregulation is central to the pathogenesis of autoimmune, degenerative, and malignant diseases. Understanding the genes and pathways that positively regulate IL-1 production provides a roadmap for therapeutic intervention. CRISPR-based functional genomics, combined with cytokine assays and transcriptomics, offers powerful tools to dissect this process. EDITGENE's knockout, point mutation, knock-in, overexpression, and library screening services enable researchers to validate causal regulators of IL-1 production and accelerate the development of targeted anti-inflammatory therapies.
References
- 1. Wang Z et al.. 2021. Autophagy-based unconventional secretion of HMGB1 by keratinocytes plays a pivotal role in psoriatic skin inflammation.. Autophagy 17(2):529-552 PMID: 32019420
- 2. Chen M et al.. 2025. Remodeling the Proinflammatory Microenvironment in Osteoarthritis through Interleukin-1 Beta Tailored Exosome Cargo for Inflammatory Regulation and Cartilage Regeneration.. ACS Nano 19(4):4924-4941 PMID: 39848926
- 4. Wang X et al.. 2025. Trem2+ Macrophages Alleviate Renal Tubule Lipid Accumulation and Ferroptosis in Diabetic Nephropathy by Repressing IL-1β-Mediated CD36 Expression.. Diabetes 74(12):2231-2248 PMID: 41042607
- 5. Dinarello CA. 1994. Interleukin-1 in disease.. Keio J Med 43(3):131-6 PMID: 7967307
- 6. Zhou Z et al.. 2018. Upregulated IL-1 Receptor-associated Kinase 1 (IRAK1) in Systemic Lupus Erythematosus: IRAK1 Inhibition Represses Th17 Differentiation with Therapeutic Potential.. Immunol Invest 47(5):468-483 PMID: 29611775
- 7. Newton RC. 1990. The production of human interleukin-1 beta by blood monocytes.. Prog Clin Biol Res 349:217-28 PMID: 2204930
- 8. Lust JA et al.. 1999. The role of interleukin-1 beta in the pathogenesis of multiple myeloma.. Hematol Oncol Clin North Am 13(6):1117-25 PMID: 10626139
